LRMR - NASDAQ
Larimar Therapeutics, Inc.
$3.20
-3.0%Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
At a Glance
Live SnapshotLarimar Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Larimar Therapeutics, Inc. Cash Flow Statement
LRMR • NASDAQ
| Larimar Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||||
-165.7M | -80.6M | -36.9M | -35.4M | -50.6M | -42.5M | -23.1M | -61.4M | -52M | -57.9M | -74.3M | -36.5M | -14M | -13.9M | -13.2M | |
-1.3M | 318K | 311K | 318K | 326K | 155K | 78K | 261K | 188K | 212K | 70K | 16K | 12K | 11K | 4K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.6M | -9.6M | 0.0 | 0.0 | -8.6M | -815K | 0.0 | 0.0 | 0.0 | |
7M | 8.8M | 0.0 | 6.6M | 5.5M | 2.2M | 129K | 173K | 0.0 | 0.0 | 8.6M | 1.6M | 0.0 | 0.0 | 0.0 | |
-281K | -5.4M | 5.7M | -820K | -15K | 10K | -3.6M | 9.8M | 9.1M | 10.6M | 9.1M | 6.7M | 645K | 218K | 78K | |
47.1M | 6.2M | -2.5M | 1.7M | 2.7M | -2M | 226K | 593K | -99K | -5.5M | 6.7M | 815K | -1.6M | 62K | 801K | |
-113.2M | -70.8M | -33.5M | -27.6M | -42.1M | -42.2M | -22.7M | -51.5M | -43.8M | -52M | -59.6M | -28.2M | -15M | -13.6M | -12.3M | |
INVESTING ACTIVITIES | |||||||||||||||
-91K | -515K | -164K | -100K | -333K | -62K | -83K | -108K | -55K | -660K | -595K | -58K | -17K | -2K | -35K | |
(0.0) | (0.0) | (0.0) | (90.9K) | -24.5K | -1.3M | -26M | (6.8M) | (0.0) | (0.0) | (91.5M) | (0.0) | (0.0) | (0.0) | (2K) | |
-83.6M | -227.9M | -101.2M | -133.6M | -8.2M | -24.5M | -82.9M | -117.1M | -114.5M | -136.5M | -287.5M | -57.2M | (0.0) | (0.0) | (0.0) | |
184M | 143M | 134.8M | 42.8M | 32.8M | 1M | 109.5M | 110.4M | 150.2M | 188.6M | 196M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -90.9K | 24.5K | 41.9M | -583K | -6.8M | 35.7M | 35K | -19K | -57K | 0.0 | 0.0 | -12K | |
(100.3M) | -85.4M | (33.4M) | -91M | (24.2M) | (17.1M) | -83K | -6.9M | (35.6M) | (51.4M) | -92.1M | -57.3M | -17K | -2K | -45K | |
FINANCING ACTIVITIES | |||||||||||||||
65.1M | 161.8M | 30K | 75.3M | 19.9M | 75.6M | 0.0 | 66.9M | 195K | 220K | 130.5M | 100.8M | 40.6M | 16.1M | 10.1M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.4M | -2.9M | -1.4M | 7.3M | 0.0 | 6M | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (67.2M) | (195K) | (220K) | (131M) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 77K | 0.0 | 0.0 | 0.0 | 18M | 19.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 13K | 0.0 | |
65.1M | 161.9M | 30K | 75.3M | 19.9M | 93.6M | 19.4M | 66.9M | 16.6M | -2.7M | 129.2M | 108.1M | 40.6M | 22.1M | 10.1M | |
CASH FLOW SUMMARY | |||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -58.1M | 0.0 | 0.0 | 0.0 | 0.0 | |
52.2M | 5.7M | -76K | -43.3M | 1.9M | 68.5M | -3.4M | 8.6M | 8.4M | -3.2M | -22.5M | 22.6M | 0.0 | 0.0 | 0.0 | |
33.8M | 28.1M | 26.8M | 71.4M | 69.5M | 1M | 4.4M | 40.8M | 32.4M | 35.6M | 58.1M | 35.5M | 9.9M | 0.0 | 0.0 | |
86M | 33.8M | 26.7M | 28.2M | 71.4M | 69.5M | 1M | 49.3M | 40.8M | 32.4M | 35.6M | 58.1M | 35.5M | 9.9M | 0.0 | |
-113.3M | -71.3M | -33.6M | -27.7M | -42.4M | -42.3M | -22.8M | -51.6M | -43.8M | -52.6M | -60.1M | -28.3M | -15M | -13.6M | -12.3M |
SEC Filings
LRMR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 19, 2026 | May 19, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | April 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 22, 2026 | January 21, 2026 | 2026 |
Related Guides
Continue your LRMR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.